Skin sensitization with the new reagents NOPYE (4-nitro-1-cyclohexyl-3-ethoxy-2-oxo-3-pyrroline) and NOPY-L-phenylalanine.
The aim of this study was to investigate the compound 4-nitro-1-cyclohexyl-3-ethoxy-2-oxo-3-pyrroline (NOPYE) and some related compounds for skin sensitization in guinea pigs, as the first step in a search for more effective skin sensitizers for immunotherapy of cutaneous tumors. In guinea pigs, NOPYE and NOPYE-L-alanine produce far milder delayed hypersensitivity reactions than DNCB. Both NOPYE and DNCB fail to act as adjuvants for skin sensitization to tuberculin purified protein derivative (PPD) and ovalbumin (OV). This suggests an explanation for the lack of effectiveness of DNCB in immunotherapy of metastases: DNCB may be relatively ineffective as an adjuvant for production of specific antitumor immunity. Such adjuvant activity may be essential if the action of the immunotherapeutic reagent is not to be confined to its site of application but is to be effective at the site of distant metastases.
D000276:Adjuvants, Immunologic; D000818:Animals; D003429:Cross Reactions; D003510:Cyclohexanes / Q000276:immunology* / Q000494:pharmacology; D004137:Dinitrochlorobenzene / Q000276:immunology; D005260:Female; D006168:Guinea Pigs; D006968:Hypersensitivity, Delayed; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy; D010047:Ovalbumin / Q000276:immunology; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000276:immunology / Q000494:pharmacology; D011758:Pyrroles / Q000276:immunology* / Q000494:pharmacology; D012867:Skin / Q000276:immunology*; D014373:Tuberculin / Q000276:immunology
C020780:4-nitro-1-cyclohexyl-3-ethoxy-2-oxo-3-pyrroline; D000276:Adjuvants, Immunologic; D003510:Cyclohexanes; D004137:Dinitrochlorobenzene; D011758:Pyrroles; D014373:Tuberculin; D010649:Phenylalanine; C023483:N-(4-nitro-1-cyclohexyl-2-oxo-3-pyrrolin-3-yl)phenylalanine; D010047:Ovalbumin